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The molecular landscape and associated clinical experience in infant medulloblastoma: prognostic
significance of second-generation subtypes
Aims: Biomarker-driven therapies have not been devel-
oped for infant medulloblastoma (iMB). We sought to
robustly sub-classify iMB, and proffer strategies for per-
sonalized, risk-adapted therapies. Methods: We charac-
terized the iMB molecular landscape, including second-
generation subtyping, and the associated retrospective
clinical experience, using large independent discovery/
validation cohorts (n = 387). Results: iMBGrp3 (42%)
and iMBSHH (40%) subgroups predominated. iMBGrp3
harboured second-generation subtypes II/III/IV. Sub-
type II strongly associated with large-cell/anaplastic
pathology (LCA; 23%) and MYC amplification (19%),
defining a very-high-risk group (0% 10yr overall sur-
vival (OS)), which progressed rapidly on all therapies;
novel approaches are urgently required. Subtype VII
(predominant within iMBGrp4) and subtype IV tumours
were standard risk (80% OS) using upfront CSI-based
therapies; randomized-controlled trials of upfront
radiation-sparing and/or second-line radiotherapy
should be considered. Seventy-five per cent of iMBSHH
showed DN/MBEN histopathology in discovery and val-
idation cohorts (P < 0.0001); central pathology review
determined diagnosis of histological variants to WHO
standards. In multivariable models, non-DN/MBEN
pathology was associated significantly with worse out-
comes within iMBSHH. iMBSHH harboured two distinct
subtypes (iMBSHH-I/II). Within the discriminated favour-
able-risk iMBSHH DN/MBEN patient group, iMBSHH-II
had significantly better progression-free survival than
iMBSHH-I, offering opportunities for risk-adapted stratifi-
cation of upfront therapies. Both iMBSHH-I and iMBSHH-
II showed notable rescue rates (56% combined post-re-
lapse survival), further supporting delay of irradiation.
Survival models and risk factors described were repro-
ducible in independent cohorts, strongly supporting
their further investigation and development.
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Conclusions: Investigations of large, retrospective
cohorts have enabled the comprehensive and robust
characterization of molecular heterogeneity within iMB.
Novel subtypes are clinically significant and subgroup-
dependent survival models highlight opportunities for
biomarker-directed therapies.
Keywords: Infant medulloblastoma, paediatric oncology, molecular pathology, risk stratification, biomarkers
Introduction
Medulloblastoma (MB), the most common malignant
paediatric brain tumour, accounts for around 10% of
childhood cancer deaths. Five-year overall survival (OS)
rates of approximately 70% are currently achieved in
non-infants (children aged over either 3 or 5 years at
diagnosis, depending on national treatment philoso-
phies) using contemporary multimodal therapies (maxi-
mal surgical resection, cranio-spinal irradiation (CSI)
and adjuvant combination chemotherapy)[1].
Infant medulloblastomas (iMB; ~30% of all MB
patients) are associated with a poorer prognosis (5-year
OS <60%) and are treated using separate approaches.
Current iMB protocols aim to minimize the perma-
nently disabling late effects associated with irradiation
of the developing brain by avoidance/delay of CSI [2].
However, this must be balanced with morbidity and
mortality, and any potential for salvage using CSI at a
later stage [3]. Desmoplastic nodular/medulloblastoma
with extensive nodularity (DN/MBEN) pathology [4]
(~40% of iMB; favourable risk) is the only clinically
adopted prognostic risk factor and is used as a basis for
de-escalation of treatment [5]; no molecular biomarkers
are in current clinical use.
Recent years have seen significant advances in our
understanding of the disease-wide molecular pathology
of medulloblastoma. The 2016 World Health Organisa-
tion (WHO) classification of brain tumours recognizes
four consensus molecular subgroups (MBWNT, MBSHH,
MBGrp3, and MBGrp4) [4], however, recent studies,
enabled by increased cohort sizes and profiling resolu-
tion, have identified intra-subgroup heterogeneity and
described further molecular subtypes within these sub-
groups [6-10]. Importantly, subgroup-directed targeted
and risk-adapted therapies are now in clinical trials for
non-infant medulloblastoma based on evidence from
biological studies in large retrospective cohorts and
clinical trials [11-13]. An equivalent evidence base
does not exist for iMB, which has, to date, typically
only been considered biologically as part of disease-
wide studies.
The first dedicated studies of the genomic landscape
of iMB are only now emerging, including first prospec-
tive characterization of clinical trials cohorts [7,14,15].
Initial findings with clinical potential have emerged.
iMBSHH subtypes have been described, however, studies
of their clinical significance have been based on mod-
estly-sized clinical cohorts (n = 25 [14], n = 76 [7]
and n = 28 [15]) and findings are inconsistent, poten-
tially due to cohort and treatment differences, and lim-
ited statistical power, within these cohorts. These
observations now require further investigation. Impor-
tantly, these studies have focused on specific subgroups
(i.e. DN/MBEN MBSHH [7], non-metastatic DN/MBEN
MBSHH [15]) and have not explored biological and clini-
cal heterogeneity within the majority of iMB (non-DN/
MBEN and non-SHH tumours represent ~60-70% of all
iMBs).
Critically, large-scale, systematic biological studies
are urgently required to establish the molecular land-
scape across all iMB disease – including incidence, bio-
logical and clinical relevance of molecular features and
novel subtypes (e.g. Group3/4 subtypes, iMBSHH sub-
types [10,13,15]) – to support future clinical advances.
In view of the limited clinical studies with biological
annotation which have been undertaken to date, the
collection and characterization of retrospective iMB
cohorts offers the prime current opportunity to address
these challenges. Importantly, in view of current strate-
gies towards treatment of iMB with radiation-sparing
approaches [15,16], and the common historical use of
radiotherapy, its impact must be carefully considered in
such retrospective studies.
We report comprehensive characterization of the
molecular pathology of iMB using large historical
cohorts, encompassing discovery in 202 patients with
full centrally reviewed clinical and pathological annota-
tion, and validation in 185 independent patients. We
demonstrate that iMBs harbour distinct biological
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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characteristics and clinically significant molecular sub-
types within the core molecular subgroups. Using these
factors, reproducible molecular subgroup-directed dis-
ease sub-classification and risk-stratification models
could be derived which are independent of upfront
radiotherapy and outperform current clinico-pathologi-
cal schemes. These models provide a basis for personal-
ized therapies, improved therapeutic strategies and
future clinical trials.
Materials and Methods
Study cohorts
A primary discovery cohort of 202 infant tumours,
<5.0 years of age (median 2.61 years) on the date of
first-line surgery, was assembled from UK Children’s
Cancer and Leukaemia Group (CCLG) institutions and
collaborating centres. All patients had systematic cen-
tral clinical review and follow up ≥5 years. Central
review of histological variants was performed to WHO
2016 criteria [4]. Full demographic and clinical data,
including treatment protocols, are given in the
Tables S1-S2. Importantly, considering the retrospective
nature of the cohort, survival and sub-total resection
(STR) rates were equivalent across the ascertainment
period (data not shown), and patients collected post-
1990 received radiotherapy at equivalent rates. A non-
infant comparator cohort (patients ages 5–16 years at
diagnosis) is detailed in Table S3. Additional indepen-
dent iMB cohorts [6,8] were used for the discovery and
validation of clinical and molecular features and for
these, institutional annotation was used. Full details of
external cohorts and subsets used thereof are given in
Table S3, including cohort selection criteria.
Procedures
Tumours were assigned to the four consensus medul-
loblastoma molecular subgroups (MBWNT, MBSHH,
MBGrp3 and MBGrp4) using established DNA methylation
array-based methods [17]. Chromosome arm-level copy
number aberrations (CNAs) were derived from these
data as previously described [18]. TP53 status was
assessed in iMBSHH where possible [4]. To identify
heterogeneity within iMBSHH, class discovery was first
undertaken using methylation array data for our pri-
mary discovery tumour cohort, then applied to two
published datasets [68], together totalling 147 iMBSHH
patients (see Data S1). Tumours were assigned to sub-
groups using a consensus of non-negative matrix fac-
torization (NMF) [9] and t-SNE/dbSCAN [8] clustering,
as previously described. For iMBGrp3, second-generation
subtypes were assigned to the combined primary dis-
covery and validation cohorts (detailed in the Data S1)
according to the ‘Grp3 and Grp4 Classifier’ found at
https://www.molecularneuropathology.org/mnp/classif
ier/7. Accession numbers for DNA methylation array
profiles used for the determination of molecular sub-
group/subtype status are GSE93646 [9], GSE85218 [8]
(Gene Expression Omnibus) and EGAS00001001953
[6] (European Genome-Phenome Archive).
Copy number status of MYC and MYCN was defined
by consensus of ≥2 of the following methods; iFISH
[19,20], MLPA, Affymetrix Genome-Wide Human SNP
Array 6.0 and/or Illumina HumanMethylation450
DNA methylation array [18]. Mutational data for
KMT2D, SUFU, PTCH1 and TP53 in our primary dis-
covery cohort were generated using the SureSelect tar-
get capture system (Agilent) and subsequent
sequencing on the Illumina HiSeq2500 instrument.
Statistical and survival analyses
All clinico-molecular features assessed in the study are
listed in Table S4; associations between features were
assessed by Chi-squared and Fisher’s exact tests. Uni-
variable and multivariable Cox proportional hazards
tests were used to investigate the association of features
with survival. Analysis was performed using SPSS v23
(SPSS, Chicago, U.S.A.) and the R statistical environ-
ment (version 3.2.3).
Expanded methodological and statistical detail can be
found in the Data S1.
Results
Key medulloblastoma features were differentially dis-
tributed between iMB (<5.0 years, n = 202) and non-
infants (5-16 years, n = 262) (Figure 1a, Figure S1).
As expected, iMBSHH (63/163, 39%) and iMBGrp3 (69/
163, 42%) were the predominant molecular subgroups
and displayed distinct molecular pathologies; iMBGrp4
was less common (n = 29/163, 18%) and WNT
tumours were largely absent (2 patients; 4.7 and
4.9 years old at diagnosis) (Table S5, Figures S1-S2).
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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Within iMB, survival was equivalent between con-
sensus molecular subgroups (5yr OS; iMBSHH 66% vs.
iMBGrp3 50% vs. iMBGrp4 61%, log rank P = 0.397)
(5yr PFS; iMBSHH 53% vs. iMBGrp3 50% vs. iMBGrp4
65%) (Figure 1b, Table S5). We thus sought to explore
the potential of further molecular heterogeneity, includ-
ing novel subtypes, to account for survival differences
within these groups. Fifty-eight per cent of our cohort
received upfront cranio-spinal radiation; we therefore
sought to understand its interaction with prognostic
features.
Within iMBSHH, two robust subgroups were identified
in our primary discovery cohort (Figure 2a, Fig-
ure S3a-c) using non-negative matrix factorization
(NMF) and t-SNE/dbSCAN. These were recapitulated
when derived in a larger, combined, cohort that
included external cohorts [6,8] not previously used for
iMB-specific assessment (Figure S3d-g). iMBSHH-I was
(b)(a)
Figure 1. Biological and clinical features of iMB differ significantly from the non-infant disease. (a) Incidence of demographic, clinical,
pathological and biological features across the age range 0-16 years, dotted line represents 5-year age at diagnosis threshold for infant
definition in this study. Abbreviations used CLA, classic; DN/MBEN, desmoplastic/nodular, medulloblastoma with extensive nodularity;
LCA, large-cell/anaplastic; iso17q, isochromosome 17q. (b) Overall survival (OS) Kaplan-Meier plot of children (childhood MB, grey
curve), all infants (iMB, black curve) and all infants by molecular subgroup (iMBSHH, red curve; iMBGrp3, yellow curve; iMBGrp4, green
curve), with at risk table (number censored in parentheses). P values are from log-rank test
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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highly associated with the recently reported SHH-b
group, whereas iMBSHH-II was enriched for SHH-a and -
c (P < 0.0001, Figure S3h) [8]. In view of this, sub-
group reproducibility/validation within our study and
compatibility of clinico-molecular correlates across
studies [7,15], the naming convention of iMBSHH-I and
iMBSHH-II was followed for clarity.
iMBSHH overall presented at a younger age (vs.
iMBGrp3; median age 1.9 years vs. 2.8 years at diagno-
sis (P < 0.0001), however, iMBSHH-I tumours presented
later than iMBSHH-II (median age 2.0 years vs.
1.4 years, P = 0.026; Figure S3i). Overall, iMBSHH was
strongly but not exclusively associated with DN/MBEN
pathologies (45/63, 71%) (Figure 2b, P < 0.0001, Fig-
ure S4); three DN/MBEN tumours in our cohort were
iMBGrp4. However, notable frequencies of CLA (n = 10,
17%) and LCA (n = 4, 7%) tumours were also observed
within iMBSHH (Figure 2c). Patients with these non-
DN/MBEN MBSHH tumours presented at an older age
(P = 0.047, Figure 2d). Mutations in PTCH1 and SUFU
were exclusively associated with iMBSHH (PTCH1, 12/
26, 46%, P = 0.002; SUFU, 7/26, 27%, P = 0.0071)
but were equivalently distributed between iMBSHH-I and
iMBSHH-II. Within iMBSHH, iMBSHH-I was significantly
enriched for classic pathology (P = 0.04), KMT2D
mutations (P = 0.001, exclusive to iMBSHH-I), chromo-
some 2 gain (P = 0.009) and loss of 20p (P = 0.016)
(Figure 2a). iMBSHH-II had a significant enrichment of
MBEN pathology (P = 0.049), 9p gain (P = 0.012) and
losses of 10q (P = 0.016) and 9q (P < 0.001). Where
assessable, these associations validated in independent
cohorts (Figure S2).
iMBSHH patients within our cohort were treated
heterogeneously, both at diagnosis and relapse
(Table S1). We therefore first assessed whether consis-
tent predictors of overall survival were observed across
iMBSHH cohorts. STR (HR 6.7, CI 2.5-17.6, P < 0.001)
and chromosome 9p gain (HR 3.3, CI 1.1-9.7,
P = 0.026) were significantly associated with poorer
OS, while DN/MBEN pathology (HR 0.2, CI 0.1-0.5,
P = 0.001) conferred a favourable risk (Figure 2e). No
other features tested (Table S4), including the novel
intra-iMBSHH molecular subtypes, metastatic disease
status or treatment variables, were significantly associ-
ated with OS. OS was equivalent between DN and
MBEN pathological variants (Figure S5e).
Based on these findings, iMBSHH was considered as a
single subgroup in cross-validated multivariable Cox
modelling of OS; this identified STR (HR 6.4 CI 2.2-
17.8, P < 0.0001) and DN/MBEN pathology (HR 0.5,
CI 0.3-0.8, P = 0.004) as independent prognostic risk
factors (Figure 2e), which validated in an independent
cohort [8] (Figure S6b). CLA/LCA and/or STR iMBSHH
tumours represented a very high-risk group (VHR; 5yr
OS 26%), with >5-fold relative-risk (log rank
P < 0.0001) compared to totally resected DN/MBEN
favourable-risk disease (FR; 5yr OS 93%) (Figure 2f-g).
These relationships were observed consistently, inde-
pendent of whether upfront radiotherapy was received
(Figure S5c).
We next assessed novel second-generation molecular
subtypes I-VIII [10] within iMBGrp3 and iMBGrp4, and
their clinico-molecular correlates, based on a combined
analysis of our primary iMBGrp3 discovery cohort and
iMBGrp3 tumours derived from two disease-wide exter-
nal cohorts [6,8] (total n = 146, Table S3). In iMBGrp3,
subtypes II (29%), III (21%) and IV (n = 44%) predom-
inated. Subtype IV was significantly associated with an
earlier age at diagnosis (<3ys, P < 0.0001), many fre-
quent CNAs and better OS (80% 5yr OS) (Figure 3a-b).
Subtype II was enriched for LCA pathology
(P < 0.001), MYC amplification (P < 0.0001), i17q
(P = 0.001) and gains of chromosome 1q, 5, 6 and 8
(all P < 0.005) and, expectedly given the enrichment
of high-risk features, had a relatively poorer 5yr OS of
32%. Subtype III had significantly fewer CNAs than
subtypes II and IV (P < 0.001) but no other character-
istic features, with a 5yr OS of 38%. iMBGrp3 samples
were occasionally, but rarely classified as subtypes V
(5yr OS 63%), I (5yr OS 60%) and VII (5yr OS 80%);
these subtypes were heavily enriched for iMBGrp4 sam-
ples; subtypes VI (5yr OS 80%) and VIII (5yr OS 83%)
were exclusively iMBGrp4 (shown for reference; Fig-
ure 3a-b). These associations also validated in indepen-
dent cohorts (Figure S2) [6,8]. Mutations were
infrequent in all iMBGrp3 and iMBGrp4 subtypes.
Notably, iMBGrp3 patients in our cohort were com-
monly treated with upfront radiotherapy, which may
contribute to survival rates observed for subtypes IV
and VII (i.e. >75% OS, Figure 3). We therefore under-
took univariable and multivariable analyses of overall
survival within iMBGrp3, considering all clinical, molec-
ular and treatment factors. In univariable analyses,
MYC amplification, LCA pathology, receipt of
chemotherapy only, isochromosome 17q and subtype II
were significantly associated with poorer OS
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
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(Figure 3c). Conversely, subtype IV, receipt of radio-
therapy and losses of chromosomes 10 and 11 pre-
dicted a better OS. Multivariable Cox modelling
identified MYC amplification (HR 4.9, CI 2.0-12.0,
P < 0.001) and LCA pathology (HR 2.4, CI 1.4-4.3,
P = 0.003) as the only independently prognostic risk
factors. Presence of either feature defined a very high-
risk group (VHR; 27% (16/62); 5yr OS 0%), with typi-
cally very short median times to relapse (4 months)
and death (5months); outcomes for this patient group
were universally dismal – in both radiotherapy-treated
and radiona€ıve patients (Figure 3, Figure S7). Remain-
ing CLA, non-MYC amplified iMBGrp3 tumours were
high risk (HR; 73% (46/62); 10yr OS 73%) (Figure 3d-
e); 36/46 (78%) of these patients were treated upfront
with radiotherapy. These relationships validated in an
independent cohort (Figure S6) [8]. Most patients who
rapidly progressed on treatment belonged to the
iMBGrp3 VHR group (n = 7/9 (78%), Figure S7).
Given the low frequency of iMBGrp4, intrasubgroup
survival modelling was not possible. Taken together,
iMBGrp4 patients belonged to a high-risk group with an
OS of 70%, but there were distinct survival outcomes
between Grp4-enriched subtypes (subtype VIII, 63%
OS, high risk; subtypes VI and VII, OS 80%, standard
risk). iMBGrp4 patients were typically older (median,
2.6 years) and almost all (19/20; 95%) were treated
with upfront radiotherapy.
We next investigated all features as predictors of pro-
gression-free survival (PFS; i.e. relapse following
upfront therapy) in iMB (Figure 4a-d). In univariable
analysis of iMBGrp3, a series of molecular (e.g. subtypes
II, IV) and clinical (e.g. receipt of CSI radiotherapy (39/
59, 66%) receipt of focal irradiation (15/59, 25%))
were significantly associated with PFS, with consider-
able overlap with findings observed for OS. In multi-
variable analyses, MYC amplification (HR 4.1, CI 1.4-
11.6, P = 0.008) and chr11 loss (HR 0.1, CI 0.06-0.5,
P = 0.002) (Figure 4a) were the only independent risk
factors for PFS.
When PFS was considered in the entire iMBSHH sub-
group, STR (HR 7.2, CI 2.3-22.8, P = 0.001) and DN/
MBEN pathology (HR 0.2, CI 0.08-0.61, P = 0.004)
(Figure 4b) were the only independent risk factors, con-
sistent with OS findings for iMBSHH. When the DN/
MBEN iMBSHH patient group was discriminated and
considered in isolation (n = 37), membership of
iMBSHH-I was significantly associated with a worse PFS
(HR 3.6, CI 1.0-11.8, P = 0.038) (Figure 4c); the only
significant predictor among all variables tested
(Table S4). In contrast, the iMBSHH-I subtype was not
significant when considered across all iMBSHH patients,
supporting the importance of diagnosing the DN/MBEN
variant within iMBSHH.
Sixty-two of iMB patients in our primary/discovery
cohort relapsed or progressed (iMBSHH n = 26; iMBGrp3
n = 25; iMBGrp4 n = 11; Figure 4e). The mean time
from diagnosis to relapse was 1.5 years. Twenty-six per
cent (14/54) of these patients received cranio-spinal
radiotherapy at relapse; 5-year OS in this group was
24  5% and 5-year post-relapse survival (PRS) was
17  4%. For iMBSHH, DN/MBEN tumours had a
greatly superior PRS (5-year PRS 60  14% vs.
9  8% for CLA/LCA) (Figure 4f, Figure S8). The
iMBSHH FR group (defined at diagnosis, Figure 2) had a
significantly better PRS than VHR counterparts (Fig-
ure S8, 5yr PRS 60% vs. 5%, P = 0.001). Comparable
findings were observed when patients who did not
Figure 2. The molecular landscape of iMBSHH and associated retrospective clinical experience. (a) Clinico-pathological and molecular
disease features are differentially distributed in iMBSHH subgroups. Membership is derived from unsupervised NMF clustering and tSNE/
dbSCAN techniques in a combined methylation array dataset (n = 155). Residuals from Fisher’s exact or v2 tests indicate where
subgroup enrichment has occurred (darker shades indicate stronger relationships); scale bar for residuals is shown. Black bar, positive for
feature; unfilled, negative for feature; grey bar, data unavailable. (b) Micrographs of H&E (haematoxylin and eosin; for general cell
morphology) and reticulin (for collagen fibres) in DN (desmoplastic/nodular) and MBEN (medulloblastoma with extensive nodularity)
tumours. Scale bar = 500lm. (c) Euler diagram showing overlap of pathology variant with iMB subgroup status. (d) Case density of age
at diagnosis in iMBSHH DN/MBEN (red line), iMBSHH non-DN/MBEN (pink) and iMBGrp4 DN/MBEN (green) groups. Box and whiskers plot
and statistical test is inset. (e) Univariable and multivariable Cox proportional hazards regression model of overall survival in discovery
cohort iMBSHH. Features which entered multivariable analysis (P < 0.1, above line; P < 0.05 shown in bold font) are indicated. Cox
proportional hazards test is shown either uncorrected (p) or corrected for multiple testing by the Benjamini-Hochberg method (adjusted
p). Additional clinical features are shown for reference (gender, age under 3 years, metastasis). (f) Summary of a novel risk-stratification
scheme for overall survival in iMBSHH. G. Kaplan-Meier plot of iMBSHH risk stratification model. At risk table (number censored in
parentheses) and log-rank test is shown. Abbreviations: STR, sub-total resection; CLA, classic; LCA, large cell/anaplastic; DN/MBEN,
desmoplastic nodular/ medulloblastoma with extensive nodularity; SHH, sonic hedgehog; CI, confidence interval; FR, favourable risk;
VHR, very high risk; M+, metastatic disease M2 or above
© 2020 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
Infant medulloblastoma 7
Time since diagnos- is (years)
1086420
O
v
e
ra
ll 
s
u
rv
iv
a
l 
(p
ro
p
o
rt
io
n
)
1.0
0.8
0.6
0.4
0.2
0.0
III IV II III IV
Residuals
IIVIVII VIIIV I
Grp3 Grp4
Second-generation Grp3/4 subtypes
male
under 3
STR
pathology
LCA
metastasis
MYC
1q gain
2q gain
4q loss
5 gain
6 gain
7 gain
8 gain
8 loss
10p loss
10 loss
11 loss
12p gain
13q loss
14q gain
15q loss
16 loss
i17q
17 gain
18 gain
21 loss
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.001
<0.001
<0.001
0.001
0.001
0.007
0.007
p value
0.462
0.326
0.596
0.023
0.042
0.035
Risk group
Time since diagnosis (years)
1086420
O
v
e
ra
ll 
s
u
rv
iv
a
l 
(p
ro
p
o
rt
io
n
)
1.0
0.8
0.6
0.4
0.2
0.0
HR 46(0) 32(8) 24(13) 17(19) 12(24) 8(26)
VHR 16(0) 1(0) 0(0)
p<0.0001
Variable n
Hazard
Rao
95% CI p adjusted p
Univariable analysis
MYC amplificaon 12/62 16.5 6.6-41.2 <0.0001 <0.0001
LCA pathology 14/62 7.8 3.5-17.6 <0.0001 <0.0001
CTX and RTX 35/59 0.2 0.1-0.5 0.001 0.006
CSI RTX 38/59 0.3 0.1-0.6 0.001 0.006
iso17q 15/61 3.9 1.7-8.7 0.001 0.006
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receive upfront radiotherapy were considered alone
(n = 24, Figure 4g). Five-year PRS rates were equiva-
lent between the novel iMBSHH subtypes (iMBSHH-I,
30%16% vs. iMBSHH-II, 33%15%, P = 0.9).
Post-relapse outcomes were dismal in iMBGrp3 (5yr
PRS 10%7%), irrespective of novel subtypes and
treatment received at relapse; most deaths (n = 14,
82%) occurred within a year (median 2 months, IQR
0.5-7). Eighty-eight per cent (n = 7/8) of radiona€ıve
iMBGrp3 patients died within 3 months of relapse,
despite a period of remission; only 2 patients received
second-line radiotherapy due to rapid disease progres-
sion (Figure 4e). For iMBGrp4, 11/29 patients relapsed
(mean time to relapse, 2.5 years; all PRS <2 years).
Integration of our validated subgroup-dependent OS
and PFS prognostication schemes (Figure 2, iMBSHH
OS; Figure 3, iMBGrp3 and iMBGRP4 OS; PFS, Figure 4)
allow the sub-classification of iMB patients into schema
for the stratified delivery of risk-adapted therapies,
based on the biomarkers discovered and therapies used
in our retrospective cohorts (Figure 5a). Overall risk
can be stratified straightforwardly using four validated
features; consensus molecular subgroup, pathology
variant, extent of resection and MYC amplification.
This subgroup-directed model (Figure 5b) significantly
outperformed the current, pathology-based, risk stratifi-
cation [5] (5yr OS AUC 0.744 vs. 0.580) in our cohort,
and was independently reproducible (FR 5yr OS 94%;
HR 5yr OS 73%; VHR 5yr OS 46%; log-rank
P < 0.001; Figure S6). Following definition of DN/
MBEN iMBSHH using this model, further distinction of
the iMBSHH-I and iMBSHH-II subtypes enables prediction
of PFS (Figure 4), while MBGroup3/4 subtypes associated
with 60-80% OS following upfront CSI are highlighted
(Figure 3) for further clinical investigation (Figure 5a).
Discussion
Our analysis of almost 400 iMB tumours provides criti-
cal insights into their subgroup-dependent molecular
heterogeneity, its clinical relevance and potential for
exploitation towards disease sub-classification and
improved, risk-adapted, therapies. Assessment of these
large retrospective cohorts has enabled robust definition
of the nature and reproducibility of molecular subtypes
within iMBSHH (types I, II) and iMBGroup3 (types I-VII),
and their interaction with established disease biomark-
ers. Consideration of their clinical associations across
independent cohorts provides strong supporting evi-
dence for their incorporation into future research stud-
ies and clinical application.
Radiation-sparing approaches have been postulated
for iMB in an effort to obviate patients from deleterious,
often life-limiting, late effects caused by treatment. Any
biomarker discovery study based on retrospective
cohorts must therefore consider the impact of radiation
therapy. Our study identified risk-stratification groups
that were reproducible and independent of receipt of
radiotherapy. First, DN/MBEN was confirmed as a
favourable-risk biomarker in our cohorts, highly associ-
ated with iMBSHH. Importantly, a notable proportion of
CLA and LCA iMBSHH tumours were observed, which
were associated with a very poor prognosis in both dis-
covery and validation cohorts irrespective of therapy,
clearly demonstrating that defining subgroup alone is
insufficient for risk stratification in iMBSHH. Central
Figure 3. The molecular landscape of iMBGroup3/4 and associated retrospective clinical experience. (a) Clinico-pathological and molecular
disease features are differently distributed in iMBGrp3 subtypes II, III and IV, as determined by use of the Grp3 and Grp4 classifier
published by Sharma et al [10] in a combined cohort (n = 146) encompassing our primary discovery cohort and published cohorts from
Northcott et al and Cavalli et al (Table S1). Residuals from Fisher’s exact or v2 tests indicate where subgroup enrichment has occurred
(darker shades indicate stronger relationships); scale bar for residuals is shown. Remaining second-generation molecular subtypes V, I
and VII (rarely iMBGrp3) and VI and VIII (exclusively iMBGrp4) are shown for reference. Black bar, positive for feature; unfilled, negative
for feature; grey bar, data unavailable (b) Kaplan-Meier plot of overall survival for second-generation molecular subtypes with frequency
>5% from our primary discovery cohort and the Cavalli et al external discovery/validation cohort. Subtypes with a frequency of >5% of
iMB are shown (II, III, IV and VII). At risk table (number censored in parentheses) and p value from log-rank test is shown. (c)
Univariable and multivariable Cox proportional hazards regression model of overall survival in discovery cohort iMBGrp3. Features which
entered multivariable analysis (P < 0.1; P < 0.05 shown in bold font) are indicated. Cox proportional hazards test is shown either
uncorrected (p) or corrected for multiple testing by the Benjamini-Hochberg method (adjusted p). Additional clinical features are shown
for reference (gender, age under 3 years, metastasis). (d) Summary of a novel risk-stratification scheme for overall survival iMBGrp3
(n = 62). E. Kaplan-Meier plot of iMBGrp3 risk stratification. At risk table (number censored in parentheses) and log-rank test are shown.
Abbreviations: STR, sub-total resection; CLA, classic; LCA, large cell/anaplastic; CI, confidence interval; HR, high risk; VHR, very high
risk; RTX, radiotherapy; CTX, chemotherapy; M+, metastatic disease M2 or above
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histological review to WHO 2016 [4] standards was
essential for the robust definition of histological vari-
ants; in our experience, 8/62 iMBSHH tumours were
reclassified to DN/MBEN from their institutional CLA
diagnosis.
Two discrete and reproducible molecular subtypes –
iMBSHH-I and iMBSHH-II – were discriminated in our
analysis of a unified iMBSHH cohort totalling 155
tumours, encompassing patients from three indepen-
dent studies [6,8]. This further supports the repro-
ducibility of these molecular subtypes, as reported in
previous studies [7,8,14,15], and defines their charac-
teristics in large cohorts. Following discrimination of
the favourable-risk iMBSHH DN/MBEN group, definition
of iMBSHH molecular subtypes enabled prediction of PFS
within our cohort, as a potential basis for the stratified
delivery of upfront therapy. DN/MBEN iMBSHH-II had
significantly improved PFS over iMBSHH-I independent
of whether upfront radiotherapy was received. The
prognostic significance of iMBSHH-I and iMBSHH-II sub-
types differs between reported studies, which likely
relates to differences in therapy and statistical power.
Our study (large retrospective cohort; n = 37 DN/
MBEN iMBSHH, mixed therapies) and SJYC03 (clinical
trial; n = 42 DN/MBEN iMBSHH, risk-adapted therapies;
no differences between low-, intermediate- and high-
risk strata [7]) showed improved PFS for iMBSHH-II.
Conversely, HIT-2000 (clinical trial; n = 28 non-meta-
static DN/MBEN iMBSHH, intraventricular methotrexate
therapy [15]) reported equivalent PFS for both groups.
Two further cohorts, ACNS1221 (clinical trial, n = 25
DN/MBEN iMBSHH, conventional systemic chemother-
apy without intraventricular methotrexate [14]) and
the HIT group/Burdenko Institute validation cohort (re-
strospective cohort, n = 48 DN/MBEN iMBSHH, mixed
therapies [15]) did not show a statistically significant
difference in PFS between iMBSHH-I and iMBSHH-II sub-
types.
Controlled clinical trials using stratified therapeutic
approaches should be considered for the DN/MBEN
iMBSHH-II patient group, aimed at resolving its interac-
tion with different therapies and minimizing therapy-in-
duced late effects, while maintaining OS rates. We
observed equivalent rates of rescue, which commonly
involved radiotherapy, in both iMBSHH subtypes, further
supporting such trials of risk-adapted therapies.
Our studies also reveal clinically actionable sub-
groups within iMBGrp3. LCA pathology and MYC ampli-
fication are enriched in subtype II. Together or in
isolation, they define a VHR group associated with a
dismal prognosis (10yr OS 0%) and a short time to
death, whether or not upfront radiation was received.
These patients are refractory to current conventional
treatments and often progress rapidly, with many not
surviving to initiation of adjuvant therapy.
A series of better prognosis subgroups within iMBGrp3
and iMBGrp4 were noted. These include subtype IV (de-
fined by many frequent CNAs [21]; 80% 5yr OS), sub-
type VII (iMBGrp4 enriched; 80% OS) and non-MYC/
non-LCA iMBGrp3 (73% OS). However, the overwhelm-
ing majority (>75%) of these patients received standard
upfront radiotherapy, and therefore the prognostic rele-
vance of these groups in the radiona€ıve iMB setting,
and the associated use of post-relapse radiotherapy as a
rescue strategy, requires further assessment.
We also assessed iMB prognostic factors defined in
previous historical studies, in our cohort [5]. Metastatic
disease was enriched in iMBGrp3, but was not signifi-
cantly associated with poorer survival (Figure 3). Its
prognostic relevance, and its interaction with radiother-
apy, thus remains unconfirmed in this patient group.
Similarly, in a previous iMB cohort, STR was
Figure 4. Progression-free survival and outcomes post-relapse, in iMB. a, b. PFS data from the discovery cohort was analysed.
Univariable and multivariable Cox proportional hazards analysis of progression survival in iMBGrp3 (a), iMBSHH (b) and in DN/MBEN
iMBSHH only (c). Features which entered multivariable analysis (P < 0.1; P < 0.05 shown in bold font) are indicated. (d) Progression-free
survival Kaplan-Meier plot comparing iMBSHH-I and iMBSHH-II in a DN/MBEN only iMBSHH cohort. (e) Summary of key clinical features in
relapsed iMB (n = 61). Patients are shown in columns. Black bar, positive for feature; unfilled, negative for feature; grey bar, data
unavailable. (f) Kaplan-Meier plot of post-relapse survival, comparing iMBSHH split by pathology status, iMBGrp3 and, for reference,
iMBGrp4. (g) Kaplan-Meier plot of post-relapse survival in a radiona€ıve cohort (patients who did not receive radiotherapy at diagnosis,
n = 28). For all Kaplan-Meier plots, at risk tables (number censored in parentheses), log-rank test and proportion receiving radiotherapy
(focal or CSI and with or without adjunctive chemotherapy), at diagnosis, are shown. Abbreviations: STR, sub-total resection; CLA,
classic; LCA, large cell/anaplastic; DN/MBEN, desmoplastic nodular/ medulloblastoma with extensive nodularity; SHH, sonic hedgehog;
CI, confidence interval; RTX, radiotherapy; CTX, chemotherapy; M+, metastatic disease M2 or above; MYC, MYC amplification; PD,
progressive disease
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significantly associated with poorer OS [5]. Our analy-
sis demonstrated its independent prognostic significance
in iMBSHH; while this may reflect historic surgical prac-
tices, outcomes for, and rates of, STR were equivalent
across our collection period. Receipt of upfront focal
radiotherapy was not associated with improved PFS
within iMBSHH (data not shown). However, receipt of
focal radiotherapy was associated with improved PFS
(compared to no irradiation) in iMBGrp3 in univariable
analyses. This finding is likely contributed to by the
high frequency of very-high-risk iMBGrp3 patients in
our cohort who received no radiotherapy at all, likely
due to a clinical decision to palliate at diagnosis.
To allow maximal inclusion and assessment of clin-
ico-biological relationships we selected patients up to
5 years of age for analysis, however, applying our sub-
group-directed survival model reached equivalent find-
ings when restricted to patients under 3 years old in
our cohort (Figure S9). This, coupled with the recent
identification of age-dependent molecular subtypes
within MBSHH (MBSHH-Infant, <4.3 years vs. MBSHH-Child-
hood) [9], suggests that the definition of the infant dis-
ease should include patients at the upper end of the 3-
5 age range in current clinical use.
As discussed for DN/MBEN iMBSHH and its subtypes,
both treatment and prognostic effects may differ
between clinical studies. Similarly, our retrospective
study encompassed patient cohorts treated with mixed
protocols. As far as possible, we controlled for age and
therapy type in our survival analyses and risk mod-
elling, and validated findings across large independent
cohorts. This has enabled the identification and valida-
tion of clinically actionable biological subgroups with
distinct and reproducible disease behaviours (favour-
able-risk DN/MBEN iMBSHH, very-high-risk LCA/MYC
iMBGrp3), which are independent of treatment. Cohort-
specific or treatment-dependent effects, particularly
with regard to emerging therapeutic concepts in iMB
(e.g. high-dose chemotherapy, intrathecal therapies)
must be considered in future clinically controlled stud-
ies.
In summary, assessment of the molecular pathology
of iMB in large historic cohorts has allowed the robust
characterization of each iMB molecular subgroup and
the novel molecular subtypes they harbour. Almost a
third of iMB can be reclassified into a VHR group,
which, based on their dismal outcomes and rapid dis-
ease course, should be urgently considered for novel
upfront therapeutic approaches, such as anti-MYC
therapeutics [22]. Prognostic subtypes within FR
groups (e.g. DN/MBEN iMBSHH-I, iMBSHH-II) offer oppor-
tunities to direct the stratified use of upfront therapies.
Identified HR iMB groups, with 60-80% survival rates
using CSI-based regimes, are suitable for investigation
in randomized clinical trials.
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